Heart Failure, Diastolic Clinical Trial
— TREND-HFOfficial title:
High Versus Moderate Intensity Endurance Exercise Training in Treating Diastolic Heart Failure
The purpose of this study is to determine whether endurance exercise of either high or
moderate intensity can reverse structural and functional changes of the heart in patients
with diastolic heart failure, and to investigate which type of exercise is best in terms of
aerobe capacity and quality of life.
The investigators expect that high intensity endurance exercise is superior to moderate
intensity endurance exercise.
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | December 2015 |
Est. primary completion date | December 2015 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Sedentary lifestyle - Normal systolic function left ventricular ejection fraction (LVEF) < 50% - New York Heart Association (NYHA) class II or III - Diastolic dysfunction (E/é < 15 or E/é 8-15 and N-terminal proBNP > 220pg/ml) - Medically stable the last 4 weeks - Written informed consent Exclusion Criteria: - Other causes of dyspnea than diastolic heart failure - Personal preferences or characteristics prohibiting the person from attending inpatient cardiac rehabilitation - Not able to perform physical exercise |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Norway | LHL Klinikkene | Røros |
Lead Sponsor | Collaborator |
---|---|
Norwegian University of Science and Technology | LHL-Klinikkene, Feiring, LHL-Klinikkene, Røros |
Norway,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in aerobic capacity measured as oxygen consumption | Cardiopulmonary exercise test | Baseline and 7 months | No |
Secondary | Feasibility, measured as attrition rate and compliance with exercise | Baseline to 7 months | No | |
Secondary | Blood-risk profile, measured as changes in cholesterol, hemoglobin, N terminal-proBNP | Baseline to 7 months | No | |
Secondary | Cardiac function measured as volume, size, efficacy | Ultrasound | Baseline to 7 months | No |
Secondary | Arterial function measured as blood-vessel elasticity | Ultrasound | Baseline to 7 months | No |
Secondary | Quality of life | Self-reported questionnaires | Baseline to 7 months | No |
Secondary | Changes in everyday activity level | Self-reported questionnaire, diary, activity monitoring device | Baseline to 7 months | No |
Secondary | Change in diastolic filling pressure measured as E/é | Ultrasound | Baseline to 7 months | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Enrolling by invitation |
NCT04573166 -
Personalized Atrial Septostomy for Heart Failure
|
N/A | |
Recruiting |
NCT02425371 -
Optimized Management of Comorbidity in Heart Failure With Preserved Ejection Fraction in the Elderly (>60 Years)
|
Phase 3 | |
Terminated |
NCT03312387 -
Muscle, Essential Amino Acids, and eXercise in Heart Failure
|
N/A | |
Completed |
NCT05475028 -
Network Medicine Approaches to Classify Heart Failure With PReserved Ejection Fraction by Signatures of DNA Methylation and Point-of-carE Risk calculaTors (PRESMET)
|
||
Recruiting |
NCT04950218 -
The Psoriasis Echo Study
|
||
Completed |
NCT02334891 -
Kyoto Congestive Heart Failure Study
|
||
Recruiting |
NCT05577819 -
Prevalence and Prediction of ATTR in Ambulatory Patients With HFpEF
|
N/A | |
Completed |
NCT05139472 -
Impact of Empagliflozin on Functional Capacity in Heart Failure With Preserved Ejection Fraction
|
Phase 3 | |
Recruiting |
NCT04682704 -
The Effect of Different Low-Level Tragus Stimulation Parameters On Autonomic Nervous System Function
|
N/A | |
Completed |
NCT03924479 -
Respiratory Muscle Function in Heart Failure
|
N/A | |
Recruiting |
NCT03830957 -
Efficacy and Safety of Ivabradine to Reduce Heart Rate Prior to Coronary CT-angiography in Advanced Heart Failure: Comparison With β-Blocker
|
N/A | |
Completed |
NCT02589977 -
Myocardial Perfusion, Oxidative Metabolism, and Fibrosis in HFpEF
|
Phase 4 | |
Completed |
NCT02946476 -
Prognostic Impact of Noncardiac Comorbidities in Heart Failure Patients
|
N/A | |
Recruiting |
NCT04179643 -
NAN-101 in Patients With Class III Heart Failure
|
Phase 1 | |
Recruiting |
NCT05425459 -
RESPONDER-HF Trial
|
N/A | |
Completed |
NCT04940312 -
MyoMobile Study: App-based Activity Coaching in Patients With Heart Failure and Preserved Ejection Fraction
|
||
Recruiting |
NCT04602338 -
Diagnosis and OutcoMes evaluAtIoN of Multicenter Patients With HFpEF Using Multimodality Imaging
|
||
Completed |
NCT03240237 -
CCM in Heart Failure With Preserved Ejection Fraction
|
N/A | |
Recruiting |
NCT05887271 -
A Randomised, Controlled Trial of a Low-energy Diet for Improving Functional Status in Heart Failure With PRESERVED Ejection Fraction Preserved Ejection Fraction
|
Phase 2/Phase 3 | |
Recruiting |
NCT05479669 -
Value of Intense Phenotyping in Heart Failure With Preserved Ejection Fraction
|